Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia?

Br J Haematol. 2019 Oct;187(2):e33-e35. doi: 10.1111/bjh.16154. Epub 2019 Aug 26.

Authors

Sumeet Mirgh¹, Rayaz Ahmed¹, Narendra Agrawal¹, Vishvdeep Khushoo¹, Ambar Garg¹, Shinto Francis¹, Narender Tejwani¹, Neha Singh¹, Dinesh Bhurani¹

Affiliation

¹ Department of Haematology and BMT, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.

PMID: 31452197
DOI: 10.1111/bjh.16154

No abstract available

Keywords: daratumumab; early thymic precursor T-acute lymphoblastic leukaemia; immunotherapy; leukaemia; refractory; stem cell transplantation.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Humans
Male
Middle Aged
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / blood*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*

Substances

Antibodies, Monoclonal
daratumumab